LifeVantage Corporation (LFVN)

Market Cap	213.24M
Revenue (ttm)	196.01M
Net Income (ttm)	4.13M
Shares Out	12.53M
EPS (ttm)	0.32
PE Ratio	53.64
Forward PE	22.63
Dividend	$0.16 (0.93%)
Ex-Dividend Date	Dec 2, 2024

Volume	41,312
Open	17.14
Previous Close	17.36
Day's Range	17.00 - 17.94
52-Week Range	5.22 - 18.41
Beta	0.89
Analysts	Strong Buy
Price Target	26.00 (+52.72%)
Earnings Date	Jan 28, 2025

About LFVN

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduc...

• Industry: Packaged Foods
• Sector: Consumer Staples
• CEO: Steven Fife
• Employees: 222
• Stock Exchange: NASDAQ
• Ticker Symbol: LFVN
• Website: https://www.lifevantage.com

Financial Performance

In 2024, LifeVantage's revenue was $200.16 million, a decrease of -6.20% compared to the previous year's $213.40 million. Earnings were $2.94 million, an increase of 15.63%.

Analyst Forecast

According to one analyst, the rating for LFVN stock is "Strong Buy" and the 12-month stock price forecast is $26.0.

Price Target

$26.0

(52.72% upside)

Analyst Consensus: Strong Buy